跳至主要内容
临床试验/ACTRN12605000583640
ACTRN12605000583640招募中1 期

A randomised placebo controlled study to evaluate the effects of zoledronic acid in reducing the progression of erosions in psoriatic arthritis.

niversity of Auckland0 个研究点目标入组 50 人开始时间: 2005年10月4日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
20 Years 至 ot stated(—)
性别
All

入选标准

  • Psoriatic arthritis (according to Vasey and Espinoza criteria)Erosive PsA (bone lysis/ erosion peripheral joints on XR confirmed by a radiologist). Disease duration > 6 months. Suitable for MR scan* Adequate contraception if applicable DMARD, on a stable dose for 8 weeks prior to randomization Oral Prednisone no > 10mg daily at least 3 swollen and 3 tender joints.

排除标准

  • Severe kidney, liver or heart disease Deranged calcium or Vit D levelsUveitis, Iritis, or chronic Conjunctivitis (or history of these conditions)Diabetic eye or kidney disease Uncontrolled diabetes, Hb1AC > 10 % Cancer (metastatic cancer or cancer diagnosed < 2 years ago) Is pregnant or planning pregnancy Severe dental problems or current dental infection, recent or impending dental surgery within three months of enrolmentOrthopaedic surgery within 3 months of enrolment Fractures (within the last 3 months) Use of Bisphosphonate therapy Participant in any biologics trial within 6 months.

研究者

发起方
niversity of Auckland

相似试验